Clinical Trials Sponsored by Stem Cell Therapeutics Corp.

Total 5 results

Stem Cell Therapeutics Corp.

Withdrawn

REGENESIS (US): A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients (REGENESIS)

Stroke

United States
Stem Cell Therapeutics Corp.

Terminated

Study of NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients (REGENESIS-LED)

Stroke

Canada, India, United States
Stem Cell Therapeutics Corp.

Terminated

REGENESIS (CA): A Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients (REGENESIS)

Stroke

Canada, India
University of Calgary
Stem Cell Therapeutics Corp.

Unknown

Safety Study of Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Traumatic Brain Injury: Dosing Tier 1

Traumatic Brain Injury

Canada
University of California, Irvine
Hoag Memorial Hospital Presbyterian; Stem Cell Therapeutics Corp.

Completed

Beta-hCG + Erythropoietin in Acute Stroke (BETAS)

Acute Stroke

United States

3

Subscribe